AlphaCentric Advisors’s Caribou Biosciences CRBU Stock Holding History

AlphaCentric Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$241K	Buy	+16,000	New	+$311K	0.07%	92

Other funds holding CRBU

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

AlphaCentric Advisors's CRBU Position: Q4 2021 in Review

AlphaCentric Advisors opened a new position in Caribou Biosciences (CRBU) in Q4 2021: 16,000 shares worth $241K. The stake represents 0.07% of the portfolio and ranks #92 among its holdings.

93 funds tracked by Wall St. Rank hold CRBU as of Q4 2021.

AlphaCentric Advisors held 16,000 shares of Caribou Biosciences worth $241K as of Q4 2021.
Caribou Biosciences was a new AlphaCentric Advisors position in Q4 2021.
Caribou Biosciences made up 0.07% of AlphaCentric Advisors's portfolio in Q4 2021, its #92 holding.
93 funds tracked by Wall St. Rank held Caribou Biosciences as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.